There was new hope for Scottish patients with prostate cancer this week after cost regulators approved funding for the use of Ferring's Firmagon on the National Health Service. There was new hope for ...

Men with advanced hormone-dependent prostate cancer and spinal metastases are to gain routine access to Ferring's Firmagon on the NHS after a NICE u-turn saw the cost regulator issue final draft ...

Ferring’s Firmagon (degarelix) has been recommended for use by the NHS in England by the country’s cost-effectiveness watchdog NICE. It follows a protracted appeals process over 2014 guidance that had ...

A successful appeal against NICE's decision on prostate cancer drug Firmagon (degarelix) means the UK's cost-effectiveness regulator will re-examine the evidence for its use in advanced cases of the ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hgtc2g/firmagon) has announced the addition of GlobalData's new report ...

Ferring Pharmaceuticals confirmed today that, following an oral hearing in London on 25 June, the panel upheld Ferring's appeal against the National Institute for Health and Care Excellence (NICE)'s ...

FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its ...

MILAN, Italy, March 16 (UPI) -- Data shows lower cardiovascular risk with Firmagon, a hormonal therapy for prostate cancer, compared with other prostate treatments, European researchers say. Bertrand ...

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for ...

While degarelix has been well studied in clinical trials, it is important to examine its efficacy and tolerability in everyday clinical practice. Clinical trials give important data about treatment ...